News & Events

Fawzi Abu Rous: Turning KRAS From “Undruggable” to a Targetable Driver in NSCLC

Fawzi Abu Rous: Turning KRAS From “Undruggable” to a Targetable Driver in NSCLC

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Orion Pharma Testing Pan-TEAD Inhibitor Combos in KRAS-Mutated NSCLC, Other Solid Tumors

Orion Pharma Testing Pan-TEAD Inhibitor Combos in KRAS-Mutated NSCLC, Other Solid Tumors

Zoldonrasib Yields Encouraging Activity in KRAS G12D+ NSCLC

Zoldonrasib Yields Encouraging Activity in KRAS G12D+ NSCLC

Zoldonrasib Yields Encouraging Activity in KRAS G12D+ NSCLC

Zoldonrasib Yields Encouraging Activity in KRAS G12D+ NSCLC

Clinical Trial: A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage...

Clinical Trial: A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage...

Jonathan W. Riess on Zoldonrasib Effectiveness in Previously Treated KRAS G12D NSCLC – AACR

Jonathan W. Riess on Zoldonrasib Effectiveness in Previously Treated KRAS G12D NSCLC – AACR

Next-Generation KRAS G12C Inhibitor Shows 'Robust' Efficacy in Advanced Lung Cancer

Next-Generation KRAS G12C Inhibitor Shows 'Robust' Efficacy in Advanced Lung Cancer

Zoldonrasib shows promise in KRAS G12D lung cancer

Zoldonrasib shows promise in KRAS G12D lung cancer